Ciurea, Adrian
Distler, Oliver
Kwok, Kenneth
Jo, Hyejin
Wang, Lisy
Killeen, Tim
Ospelt, Caroline
Frank Bertoncelj, Mojca
Funding for this research was provided by:
Pfizer Inc
Article History
Received: 17 November 2022
Accepted: 23 August 2023
First Online: 29 September 2023
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki, International Council for Harmonisation Guidelines for Good Clinical Practice, and local country regulations. The institutional review board at each study center and relevant independent ethics committees approved the study, and all patients provided written informed consent.
: Not applicable.
: AC has received honoraria for lectures from AbbVie, MSD, and Novartis. OD has/had a consultancy relationship with and/or has received research funding from and/or has served as a speaker for the following companies in the last three calendar years: 4P-Pharma, AbbVie, Acceleron, Alcimed, Altavant, Amgen, AnaMar, Arxx, AstraZeneca, Bayer, Beacon, Blade, Boehringer Ingelheim, Corbus, CSL Behring, Galapagos, Galderma, Glenmark, Gossamer, Horizon, Inventiva, IQVIA, Janssen, Kymera, Lupin, Medscape, Merck, Miltenyi Biotec, Mitsubishi Tanabe, Novartis, Prometheus, Redx Pharma, Roivant, Sanofi, and Topadur. Patent issued “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143). KK and LW are employees and shareholders of Pfizer Inc. HJ is a former employee of Syneos Health, who were paid contractors to Pfizer in the development of this manuscript. TK is an employee of Pfizer AG and a shareholder of Pfizer Inc. CO has declared no potential disclosures of interest. MFB has received grants and/or research support from AbbVie.